Next Article in Journal
Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction— Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data from European Society of Cardiology Heart Failure Registries)
Previous Article in Journal
Acute Changes in Heart Rate Variability to Glucose and Fructose Supplementation in Healthy Individuals: A Double-Blind Randomized Crossover Placebo-Controlled Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biology
Volume 11
Issue 2
10.3390/biology11020340
biology-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database

by
Shruti Rastogi
1,2,
Vivekanandan Kalaiselvan
2,
Yousef A. Bin Jardan
3,
Saima Zameer
4 and
Maryam Sarwat
1,*
1
Amity Institute of Pharmacy, Amity University, Noida 201313, India
2
Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, Ghaziabad 201002, India
3
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
4
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, USA
*
Author to whom correspondence should be addressed.
Biology 2022, 11(2), 340; https://0-doi-org.brum.beds.ac.uk/10.3390/biology11020340
Submission received: 13 January 2022 / Revised: 9 February 2022 / Accepted: 16 February 2022 / Published: 21 February 2022
Browse Figures
Versions Notes

Abstract

:

Simple Summary

The most commonly reported adverse drug reactions (ADRs) related to filgrastim (FIL) and pegfilgrastim (PEG-F) were obtained and analyzed from the European EudraVigilance (EV) database. Frequently reported ADRs for FIL and PEG-F are pyrexia, bone pain, back pain, neutropenia and febrile neutropenia. No statistical difference in the probability of bone pain between FIL and PEG-F was observed. To further depict the safety of FIL and PEG-F, there is a further need to examine the real-life data.

Abstract

The primary prophylaxis with filgrastim (FIL) and pegfilgrastim (PEG-F) is recommended to decrease the severity of chemotherapy-induced neutropenia (CIN). The commonly reported adverse drug reactions (ADRs) with FIL and PEG-F is bone pain. ADRs pertaining to FIL and PEG-F were extracted from the European EudraVigilance (EV) database. The Individual Case Safety Reports (ICSRs) obtained from EV database that reported FIL and PEG-F as the suspected drug were analyzed. Registered ADRs (from the groups “General disorders and administration site conditions”, “Blood and lymphatic system disorders”, “Musculoskeletal and connective tissue disorders” and “Investigations”) for FIL and PEG-F were collected from EV database from 2007 to 5 June 2021. The reporting odds ratio (ROR) was used to calculate ICSRs with most common ADRs related to FIL and PEG-F. A total of 17,403 ICSRs described the incidence of most common ADRs of FIL and PEG-F. The commonly reported ADRs for both drugs were pyrexia, bone pain, back pain, neutropenia and febrile neutropenia. The odds ratio of ICSRs belonging to the System Organ Class (SOC) “Investigations” (ROR 1.01 (CI 0.93–1.10)) revealed no significant difference in FIL and PEG-F. However, for the SOCs (General disorders and administration site conditions” and “Musculoskeletal and connective tissue disorders” ((ROR 1.14 (CI 1.06–1.21); ROR 1.21 (CI 1.18–1.32), respectively), an increased reporting probability with PEG-F was found. The authors reported a lower reporting probability for the SOC “Blood and lymphatic system disorders” for FIL versus PEG-F (ROR 0.75 (CI 0.70–0.80)). Our results have demonstrated that the occurrence of bone pain was similar with FIL and PEG-F. For the incidence of pyrexia and back pain, PEG-F was associated with a higher reporting probability as compared to FIL. However, the incidence of neutropenia and febrile neutropenia was higher in FIL compared to PEG-F. Further evaluation of data from real life is needed.

Graphical Abstract

1. Introduction

Neutropenia and its complications, including febrile neutropenia (FN), mainly caused by cancer chemotherapy, can result in sepsis and infection, leading to oncologic emergency [1,2]. FN leads to a significant neutrophilic reduction accompanied by fever and is defined internationally as “an oral temperature of >38.3 °C or two consecutive readings of >38° for 2 h associated with an absolute neutrophil count (ANC) of less than 0.5 × 109/L or expected to fall below <0.5 × 109/L” [3]. The prevention and correct management of FN is important because the rate of major complications (e.g., acute renal failure, hypotension, and heart failure) is approximately 25% to 30% and FN mortality rate ranges from 9% to 12% [4]. The severe sepsis and hospital mortality may also be as high as 50%. In chemotherapy patients, FN results in decreasing dose, treatment delay or treatment cessation [5]. In America, the mean length of hospitalization stay for solid tumor patients was 8–11 days and for lymphoma patients was 10–11 days, thereby imposing an economic burden on patients [6,7].
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein responsible for the proliferation, differentiation and activation of hematopoietic blood cells [1,8]. Primary prophylaxis with G-CSF is recommended by international guidelines to reduce the frequency, severity, duration and risk of chemotherapy-induced neutropenia when the risk associated with FN is ≥20% [1,3]. In patients with 10% to 20% risk of FN, G-CSF must be indicated in patients with age more than 65 years, hepatic or renal dysfunction, persistent neutropenia, coexisting morbidities or prior episodes of FN. For patients with FN < 10%, no G-CSF prophylaxis is recommended [3,9,10]. The G-CSFs widely used are short-acting G-CSF (filgrastim (FIL): NEUPOGEN®, lenograstim, tbo-filgrastim and filgrastim biosimilars (FIL biosimilars)) and long-acting G-CSFs (pegfilgrastim (PEG-FIL): Neulasta® and lipegfilgrastim).
The first G-CSF to be granted approval in the U.S.A. and Europe was FIL in 1991 [11]. FIL stimulates the bone marrow to produce white blood cells (WBCs), enhances the functions of WBCs and decreases the duration and severity of neutropenia [12]. PEG-F is produced by covalently adding a 20 kDa polyethylene glycol moiety to the N-terminal methionyl residue of FIL. Thus, PEG-F tends to have a higher serum half-life and subsequently attains a higher plasma concentration [13]. Numerous trials have shown that a single dose of 6 mg PEG-F was equally effective as a daily dose of FIL (5 mcg/kg) to reduce the length of neutropenia [14,15,16,17,18]. Lipegfilgrastim, approved by the European Medicine Agency (EMA) in 2013, is a conjugate of FIL with a single polyethylene glycol molecule and approved to reduce the duration and incidence of neutropenia in chemotherapy patients [19].
Numerous studies have shown the comparable safety and efficacy of FIL and PEG-F. The frequently reported ADRs attributed to of FIL are bone pain, rash, allergic reactions, headache and splenomegaly. Among the reported ADRs, bone pain is consistently reported across all patient population [20,21]. However, ADRs associated with PEG-F includes bone pain and pain in the extremities [22]. The authors recently reported the pharmacovigilance data for cases of filgrastim and biosimilar filgrastim using VigiBase®, a WHO pharmacovigilance database [23] that confirmed that bone pain is most commonly associated an ADR of FIL innovator. However, some questions remain to be answered especially as it concernsthe relatively low reporting in Europe in the VigiBase® database. Therefore, this paper aims to identify and describe ADRs related with FIL and PEG-F using the European ADR database, EudraVigilance (EV) of the European Medicine Agency (EMA). A statistical analysis is performed and odds ratio with 95% confidence interval (CI) is calculated using the reporting odds ratio (ROR) method. This study is extremely relevant as the increase in patients exposed to chemotherapy may lead to an increase in the potentially life-threatening condition of neutropenia.

2. Methodology

2.1. Data Source

Data on ICSRs with FIL and PEG-F as the suspected drug were obtained from the European pharmacovigilance database (EudraVigilance; EV database) (www.adrreports.eu, accessed on 30 November 2021 ) from 2007 to 5 June 2021. The EV database is an interface designed to facilitate the electronic reporting of suspected ADRs and analysis of their data. The ADR reports are electronically submitted to the EV database by national medicine regulatory authorities and by Marketing Authorization Holders (MAH) [24]. The database was first launched and became operational in December 2001.
The drugs in the database are coded as per the EV database medicinal product dictionary. ADRs are coded using terms in Medical Dictionary for Regulatory Activities (MedDRA), a standardized medical terminology that helps to share the regulatory information for medical products internationally. There are five hierarchies to MedDRA for the analysis of ADR reports. The highest level of the MedDRA terminology has the lowest specificity and enables the analysis of aggregate data. In contrast, the lowest level of MedDRA terminology has the highest specificity and enables the analysis at an individual level. The Lowest Level Term (LLT) was derived from the most frequently reported ADRs by patients or healthcare professionals (HCPs). Each LLT is linked to its specific preferred term (PT) that is a descriptor term. There is no limit to the number of LLTs that are linked to PT. However, a PT must be linked to at least one LLT. These PT have superordinate descriptors as High-Level Term (HLTs), which are subordinate to “High Level Group Terms” (HLGTs). The HLGTs are linked to one System Organ Classes (SOCs). The SOC is the highest level of hierarchy and comprises the etiology, manifestation site and purpose and thus are the aggregate level of analysis [25].

2.2. Data Selection

This is a retrospective, observational, and pharmacovigilant study performed using the EV database. In the database, the valid ICSRs, which reported either FIL or PEG-F as a “suspected/interacting” drug, were identified. For each drug, the cases were retrieved using standardized MedDRA queries (SMQ). The ADRs were described in terms of the SOC term and PT term. The SOCs described were “General disorders and administration site conditions”, “Blood and lymphatic system disorders”, “Musculoskeletal and connective tissue disorders” and “Investigations”. The top reported SOCs and their subsequent top reported PTs were recognized by summarizing the suitable PT or by the application of the appropriate SMQs.

2.3. Data Analyses

Using the EV database, the following data were extracted from the ADR reports: (1) patient demographics (patient age and sex); (2) ADR information (outcome and seriousness); (3) administrative information (reporter qualification and source country for regulatory purposes); and (4) medication information (co-reported active ingredients, suspected drugs other than FIL or PEG-F).
The ADR was considered as serious if it resulted in “death”, is “life-threatening”, requires “hospitalization” or “prolonged existing hospitalization”, result in significant “disabilities” and/or is a “congenital anomaly/birth defect” [26]. The outcome of the ADR was classified based on the recovery pattern. These ADR were reported for ADRs belonging to the SOCs “General disorders and administration site conditions”, “Musculoskeletal and connective tissue disorders”, “Blood and lymphatic system disorders” and “Investigations”. The analyses in EV database were electronically based without any manual assessment of the cases.
The primary outcome of interest was the top reported ADRs: pyrexia, neutropenia, febrile neutropenia, bone pain, back pain, and arthralgia. These ADRs were identified by the MedDRA® PT term “Pyrexia”, “Neutropenia”, “Febrile Neutropenia”, “Back Pain”and “Bone Pain”. In the secondary analysis, other potential safety signals, including “drug ineffectiveness”, “arthralgia” and “thrombocytopenia”, were investigated.
The odds ratio and its 95% CI were calculated using ROR method and chi-square test was calculated to compare ADRs “Pyrexia”, “Neutropenia”, “Febrile Neutropenia”, “Back Pain” and “Bone Pain”, between FIL and PEG-F, using FIL as the reference drug. Data analysis was conducted using GraphPad prism 6.0 software (GraphPad Software, San Diego, CA, USA).

3. Results

We identified 17,403 ICRS with FIL or PEG-F as the drug suspects. Of these, 7091 ICSRs were reported for FIL and 10,312 ICSRs for PEG-F were sent to the EV database. As depicted in Figure 1, a sharp increase in the number of cases was observed in 2013 for FIL and in 2015 for PEG-F, although the data relating to 2021 is incomplete (updated 5 June 2021).
The characteristics of the ICSRs on the basis of the outcome of interest is described in Figure 2. The age group of 18–64 years experienced most ADRs in FIL (n = 3542; 50%) and PEG-F (n = 4254; 41.3%), among which the majority were females (52.1% FIL and 58.6% PEG-F). For FIL, the majority of the reports were from Italy (23.9%), France (16.0%), Germany (15.2%) and the United Kingdom (11.5%). Conversely, for PEG-F, the majority of the reports were from Germany (27.6%), followed by Netherlands (27.5%); reports from France and Italy were less than 10%. Regarding distribution by seriousness, 84.3% FIL ICSRs and 93.6% PEG-F ICSRs were considered as serious. Moreover, 14.7% FIL ICSRs and 6.3% PEG-F ICSRs were considered as non-serious. HCPs were the primary reporter of ADRs (FIL: n = 6525; 92%; PEG-F: n = 9672; 93.8%), while the non-European Economic Area (EEA) countries were the primary source (FIL: n = 3901; 55%; PEG-F: n = 6294; 61%).
Table 1 describes the frequently reported PTs for FIL and PEG-F. The top three reported ADRs for FIL include neutropenia (8.1%), pyrexia (7.8%) and febrile neutropenia (7.4%). Additionally, the top reported ADRs for PEG-F include febrile neutropenia (13.4%), neutropenia (10.9%) and bone pain (6.8%).
The patient demographic information of ADRs associated with FIL are provided in Figure 3.The most common ADR associated in with FIL in the age group of 18–64 years is pyrexia (55.5%), followed by bone pain (54.8%) and thrombocytopenia (52.5%). Regarding the outcome of ADRs, in the majority of cases, the result was unknown for FIL (47.5%) and for PEG-F (48.2%). However, 29% of the outcome was recovered/resolved in both FIL and PEG-F. In addition, 7.5% of FIL ADRs and 9.5% PEG-F ADRs were fatal (Figure 4).
The disproportionality analysis is provided in Table 2. PEG-F is associated with a high reporting of spontaneous data with ADRs belonging to the SOCs “General disorders and administration site conditions” (ROR 1.14, 95% CI 1.06–1.21) and “Musculoskeletal and connective tissue disorders” (ROR 1.21, 95% CI 1.18–1.32). Instead, the reporting probability of ICSRs was low for ICSRs related to ADRs with the SOC “Blood and lymphatic system disorders” for FIL versus PEG-F (ROR 0.75, 95% CI 0.70–0.80). No substantial difference among FIL and PEG-F was observed for the ROR of ICSRs with ADRs belonging to the SOC “Investigations” (ROR 1.01, 95% CI 0.93–1.10). For specific ADRs, a higher reporting was found for the PT terms “Pyrexia” and “Back Pain” for FIL versus PEG-F (ROR 1.16, 95% CI 1.04–1.30; ROR 1.87, 95% CI 1.57–2.22, respectively). However, the ADRs reporting low probability were neutropenia and febrile neutropenia for FIL versus PEG-F (ROR 0.72, 95% CI 0.65–0.80; ROR 0.51, 95% CI 0.46–0.57, respectively). No difference in the odds ratio among FIL and PEG-F was observed with the ADR “Bone Pain” (ROR 0.72, 95% CI 0.65–0.80). Table 3 provides the ROR belonging to the top reported ADRs for the comparison of FIL versus PEG-F.

4. Discussion

FN is the most serious complication associated with cancer chemotherapy, leading to infection and sepsis [1]. It affects quality of life by predisposing patients to long-term treatment and prolonged hospitalization [27]. G-CSF, including FIL and PEG-F, are a choice of drugs for the prophylaxis of chemotherapy-induced FN and numerous clinical trials, and daily practice has demonstrated their efficacy [1,3,28]. Indeed, previous published data comparing FIL and PEG-F have concluded similar efficacy between the two G-CSFs and the need for fewer PEG-F injections can improve the quality of life of the patient and their family.
The present article discusses the post-marketing surveillance of biotherapeutics, i.e., FIL and PEG-F. Unlike chemical entities, biotherapeutics are produced in living organisms, larger in size, and have structural and manufacturing complexities. Biotherapeutics also require adequate temperature for storage to prevent any degradation of the products. The market authorization of biotherapeutics is granted based on abbreviated pathway and ADRs previously not known during clinical trials may appear in a post-marketing setting. To our knowledge, this is the first study performed for the analysis of spontaneous ADRs of FIL and PEG-F through the EV database. The choice to evaluate the top reported ADRs was driven by the scientific evidence to understand the association between FIL and PEG-F [29]. Additionally, with the patent expiry of the FIL innovator in Europe in 2006, several biosimilars have been approved. Interestingly, the data submitted to VigiBase® were limited. Therefore, the authors chose to work on reports submitted to the European adverse drug reaction EV database to study the ADR reports of FIL and PEG-F.
In our study, we found 17,403 ICSRs reporting FIL or PEG-F as a suspect drug from the EV database. Demographic data (patients aged 18–64 years, female-sex predominant) were consistent with previously reported studies [30]. From 2008 until 2020, there was an increase in ICSR reporting for FIL and PEG-F with the highest reporting taking place in 2013. The increase in reporting is mainly attributed to the increased use of FIL and PEG-F in hospital settings. Indeed, various biosimilars of FIL have gained approval in 2008, becoming increasingly available for clinical use and since then, their demand has constantly increased [24].
Studying ICSR information on seriousness, 89.8% of cases were serious and mainly attributed to PEG-F. As for safety, comparing once-per-cycle PEG-F and daily injections of FIL, a phase III study revealed that the similar ADR profile between FIL and PEG-F [17,31]. Additionally, a meta-analysis study performed by authors identified 13 studies showing a head-to-head comparison of PEG-F and FIL [32]. In nine randomized controlled trials (RCTs), FN-related relative risk was lower for PEG-F and was not statistically significant (RR 0.90; p = 0.42). Another meta-analysis also showed statistically insignificant data (0.86; p = 0.226) among 12 of 36 RCTs, with lower FN incidence for PEG-F versus FIL. However, 24 of 36 non-RCTs non-randomized controlled trials (NRCTs) showed significantly lower risk with PEG-F than FIL for FN incidence (0.67; p = 0.023) [33]. The greater efficacy of PEG-F in NRCTs might be because of the under dosing of FIL (11 out of 12 RCTs provided greater than or equal to 7 doses of FIL versus only 2 of 24 NRCTs). When dosed homogeneously, i.e., a single dose of PEG-F and 10 to 14 days of FIL administration, the ADRs were shown to be similar [34].
Lastly, in line with previously published literature, we observed the frequent reporting of the following ADRs: pyrexia, febrile neutropenia, bone pain and back pain [35,36]. These reactions occur at neutropenia grade 1 to 2 and recovered quickly [37]. The odds ratio with ADRs belonging to the SOC “Investigations” showed no difference between FIL and PEG-F (1.01; 95% CI 0.93–1.01). An increase in the ADRs of the SOC “General disorders and administration site conditions” (1.14; 95% CI 1.06–1.21) and the SOC “Musculoskeletal and connective tissue disorders” (1.21; 95% CI 1.18–1.32) were observed with PEG-F as compared with FIL. The results of a meta-analysis of 5 RCTs (evaluating 617 patients) administered with single dose of PEG-F per cycle compared to daily FIL injections showed that the incidence of bone pain (0.95; 95% CI 0.76–1.19) was similar for FIL and PEG-F and our study confirmed the same. Additionally, in statistical testing, the Q value was not statistically significant indicating that statistical heterogeneity did not occur in the combined studies [38].
As compared with VigiBase®, an earlier study performed by the authors, the analysis in the EV database yielded more ICSRs, which may be because different countries adopt different strategies to the execution of these databases, for example, the timelines and typology of reports, definition of ADRs by HCPs and differences in the database management. The analysis on ADRs associated with FIL and PEG-F in the EV database provided an update on the published literature. The overall identified ICSRs were low and are increasing, reflecting increased consciousness among the HCPs.
The present study analyzed the safety profile of FIL and PEG from the spontaneous voluntary data obtained from the EV database. Considering the recent patent expiry of FIL and PEG-F and the approval of their respective biosimilars, our study epitomizes the first complete evaluation of pharmacovigilance data related to FIL and PEG-F. Furthermore, the data from spontaneous reporting, especially in the elderly and patients with co-morbidities, were obtained, as these patients are usually excluded in pre-marketing clinical trials. The European database allowed us to access the data from Europe of FIL and PEG-F.
However, despite its strengths, the study has a few limitations. The ADRs were reported spontaneously by the reporter in specified forms. Thus, the completeness of the reporting forms and the authenticity of data are non-heterogenous and only rely on the accuracy of the reporter. Additionally, only the numerator information on ICSRs was present, but the number of patients exposed to FIL and PEG-F is lacking. Therefore, it is difficult to quantify the overall risk associated with the drugs. The spontaneous reporting system also has the limitation of reporting bias. The authors reported the content mentioned in the spontaneous reports and the evaluation was not modified. This is because the authors did not have any access to the patients’ medical records, but only to the data provided by the source in the reporting form. Thus, spontaneous reporting is mainly affected by the under-reporting and incompleteness of information. An important limitation of the database is the impossibility to compute and provide a distinction between the FIL and PEG-F innovators and the biosimilars. Therefore, the reports of the innovator and biosimilars cannot be separated.

5. Conclusions

The descriptive analysis of safety reports related to FIL and PEG-F were carried out using the EV database. Our results demonstrated the similar occurrence of bone pain in patients administered with FIL and PEG-F. For the incidence of pyrexia and back pain, PEG-F was associated with a higher reporting probability as compared to FIL. However, the incidence of neutropenia and febrile neutropenia was higher in FIL compared to PEG-F. Additionally, the majority of the reports were serious and belonged to females. The safety of drugs cannot be concluded from clinical trials because of limited patient exposure and low follow-up with patients. Thus, spontaneous reporting of ADRs, despite of their limitations, is the main source of reporting. The adverse reactions reported with FIL and PEG-F g may affect the financial burden of treatment and may have impact on patients’ quality of life. In this context, a pharmacovigilance system guarantees the continuous monitoring of the safety of drugs and plays an essential role in accessing the benefit risk profile of these drugs.

Author Contributions

Conceptualization, S.R. and M.S.; Data curation, S.R. and V.K.; Formal analysis, S.R. and M.S.; Investigation, V.K.; Methodology, S.R., V.K. and M.S.; Project administration, M.S.; Resources, M.S.; Software, S.R.; Supervision, M.S.; Visualization, Y.A.B.J. and S.Z.; Writing—original draft, S.R., V.K. and M.S.; Writing—review and editing, S.Z., Y.A.B.J. and M.S. All authors contributed to interpreting the results, reviewing the draft, and finalizing the paper. All authors have read and agreed to the published version of the manuscript.

Funding

Researchers Supporting Project Number (RSP2022R457).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data generated from the study are clearly presented and discussed in the manuscript.

Acknowledgments

The authors would like to extend their sincere appreciation to the Researchers Supporting Project Number (RSP2022R457), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Aapro, M.; Bohlius, J.; Cameron, D.; Lago, L.D.; Donnelly, J.P.; Kearney, N.; Lyman, G.; Pettengell, R.; Tjan-Heijnen, V.; Walewski, J.; et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 2011, 47, 8–32. [Google Scholar] [CrossRef] [PubMed]
  2. Ajithkumar, T.V.; Hatcher, H. Specialist Training in Oncology E-Book; Elsevier Health Sciences: St Louis, MO, USA, 2011. [Google Scholar]
  3. Klastersky, J.; de Naurois, J.; Rolston, K.; Rapoport, B.; Maschmeyer, G.; Aapro, M.; Herrstedt, J. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann. Oncol. 2016, 27, v111–v118. [Google Scholar] [CrossRef] [PubMed]
  4. Taplitz, R.A.; Kennedy, E.B.; Bow, E.J.; Crews, J.; Gleason, C.; Hawley, D.K.; Langston, A.A.; Nastoupil, L.J.; Rajotte, M.; Rolston, K.; et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J. Clin. Oncol. 2018, 36, 1443–1453. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Wang, L.; Baser, O.; Kutikova, L.; Page, J.H.; Barron, R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: A systematic review and meta-analysis of randomized controlled trials. Support. Care Cancer 2015, 23, 3131–3140. [Google Scholar] [CrossRef] [Green Version]
  6. Caggiano, V.; Weiss, R.V.; Rickert, T.S.; Linde-Zwirble, W.T. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005, 103, 1916–1924. [Google Scholar] [CrossRef]
  7. Hirsch, B.R.; Lyman, G.H. Pharmacoeconomics of the Myeloid Growth Factors. PharmacoEconomics 2012, 30, 497–511. [Google Scholar] [CrossRef]
  8. Bennett, C.L.; Djulbegovic, B.; Norris, L.B.; Armitage, J.O. Colony-stimulating factors for febrile neutropenia during cancer therapy. N. Engl. J. Med. 2013, 368, 1131–1139. [Google Scholar] [CrossRef] [Green Version]
  9. Baden, L.R.; Swaminathan, S.; Angarone, M.; Blouin, G.; Camins, B.C.; Casper, C.; Cooper, B.; Dubberke, E.R.; Engemann, A.M.; Freifeld, A.G.; et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2016, 14, 882–913. [Google Scholar] [CrossRef]
  10. Carmona-Bayonas, A.; Jimenez-Fonseca, P.; De Castro, E.M.; Mata, E.; Biosca, M.; Custodio, A.; Espinosa, J.; Vázquez, E.G.; Henao, F.; De La Peña, F.A. SEOM clinical practice guideline: Management and prevention of febrile neutropenia in adults with solid tumors (2018). Clin. Transl. Oncol. 2018, 21, 75–86. [Google Scholar] [CrossRef] [Green Version]
  11. Welte, K.; Gabrilove, J.; Bronchud, M.H.; Platzer, E.; Morstyn, G. Filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996, 88, 1907–1929. [Google Scholar] [CrossRef] [Green Version]
  12. Mehta, H.M.; Malandra, M.; Corey, S.J. G-CSF and GM-CSF in Neutropenia. J. Immunol. 2015, 195, 1341–1349. [Google Scholar] [CrossRef] [PubMed]
  13. Molineux, G. Pegfilgrastim: Using pegylation technology to improve neutropenia support in cancer patients. Anti-Cancer Drugs 2003, 14, 259–264. [Google Scholar] [CrossRef] [PubMed]
  14. Molineux, G.; Kinstler, O.; Briddell, B.; Hartley, C.; McElroy, P.; Kerzic, P.; Sutherland, W.; Stoney, G.; Kern, B.; Fletcher, F.A.; et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp. Hematol. 1999, 27, 1724–1734. [Google Scholar] [CrossRef]
  15. Johnston, E.; Crawford, J.; Blackwell, S.; Bjurstrom, T.; Lockbaum, P.; Roskos, L.; Yang, B.-B.; Gardner, S.; Miller-Messana, M.A.; Shoemaker, D.; et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J. Clin. Oncol. 2000, 18, 2522–2528. [Google Scholar] [CrossRef]
  16. Holmes, F.; O’shaughnessy, J.; Vukelja, S.; Jones, S.; Shogan, J.; Savin, M.; Richards, D.; Glaspy, J.; Meza, L.; Cohen, G.; et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 2002, 20, 727–731. [Google Scholar] [CrossRef]
  17. Holmes, F.A.; Jones, S.E.; O’Shaughnessy, J.; Vukelja, S.; George, T.; Savin, M.; Richards, D.; Glaspy, J.; Meza, L.; Cohen, G.; et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: Amulticenterdose-finding study in women with breast cancer. Ann. Oncol. 2002, 13, 903–909. [Google Scholar] [CrossRef]
  18. Vose, J.M.; Crump, M.; Lazarus, H.; Emmanouilides, C.; Schenkein, D.; Moore, J.; Frankel, S.; Flinn, I.; Lovelace, W.; Hackett, J.; et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J. Clin. Oncol. 2003, 21, 514–519. [Google Scholar] [CrossRef]
  19. Agency, E.M. European Public Assessment Report for Lonquex. 2013. Available online: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summaryforthepublic/human/002556/WC500148383.pdf (accessed on 30 October 2021).
  20. Welte, K.; Reiter, A.; Mempel, K.; Pfetsch, M.; Schwab, G.; Schrappe, M.; Riehm, H. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. Blood 1996, 87, 3143–3150. [Google Scholar] [CrossRef] [Green Version]
  21. Murata, M.; Harada, M.; Kato, S.; Takahashi, S.; Ogawa, H.; Okamoto, S.; Tsuchiya, S.; Sakamaki, H.; Akiyama, Y.; Kodera, Y. Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors. Bone Marrow Transplant. 1999, 24, 1065–1071. [Google Scholar] [CrossRef] [Green Version]
  22. Kubo, K.; Miyazaki, Y.; Murayama, T.; Shimazaki, R.; Usui, N.; Urabe, A.; Hotta, T.; Tamura, K. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE (R) chemotherapy for malignant lymphoma. Br. J. Haematol. 2016, 174, 563–570. [Google Scholar] [CrossRef]
  23. Rastogi, S.; Shukla, S.; Sharma, A.K.; Sarwat, M.; Srivastava, P.; Katiyar, T.; Kalaiselvan, V.; Singh, G.N. Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data. Toxicol. Appl. Pharmacol. 2020, 395, 114976. [Google Scholar] [CrossRef] [PubMed]
  24. Postigo, R.; Brosch, S.; Slattery, J.; van Haren, A.; Dogné, J.M.; Kurz, X.; Candore, G.; Domergue, F.; Arlett, P. EudraVigilance medicines safety database: Publicly accessible data for research and public health protection. Drug Saf. 2018, 41, 665–675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Mozzicato, P. MedDRA. Pharm. Med. 2009, 23, 65–75. [Google Scholar] [CrossRef]
  26. di Mauro, G.; Zinzi, A.; Scavone, C.; Mascolo, A.; Gaio, M.; Sportiello, L.; Ferrajolo, C.; Rafaniello, C.; Rossi, F.; Capuano, A. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. Drug Saf. 2020, 44, 337–349. [Google Scholar] [CrossRef] [PubMed]
  27. MacDonald, K.E.; Hayley Bee, B.; Darby Tozer, B.; Train, J.E. Impact on Patients and Families. Oncology Nurse Advisor. 2012, pp. 29–32. Available online: https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2019/01/ona_filgrastim0612_8956.pdf (accessed on 24 September 2021).
  28. Leonard, R.C.F.; Mansi, J.L.; Keerie, C.; Yellowlees, A.; Crawford, S.; Benstead, K.; Matthew, R.; Adamson, D.; Chan, S.; Grieve, R. A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann. Oncol. 2015, 26, 2437–2441. [Google Scholar] [CrossRef]
  29. Moore, D.C.; Pellegrino, A.E. Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management. Ann. Pharmacother. 2017, 51, 797–803. [Google Scholar] [CrossRef]
  30. Lyman, G.H.; Lalla, A.; Barron, R.L.; Dubois, R.W. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. Clin. Ther. 2009, 31, 1092–1104. [Google Scholar] [CrossRef]
  31. Green, M.D.; Koelbl, H.; Baselga, J.; Galid, A.; Guillem, V.; Gascon, P.; Siena, S.; Lalisang, R.I.; Samonigg, H.; Clemens, M.R.; et al. A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. 2003, 14, 29–35. [Google Scholar] [CrossRef]
  32. Rastogi, S.; Kalaiselvan, V.; Ali, S.; Ahmad, A.; Guru, S.A.; Sarwat, M. Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis. Biology 2021, 10, 1069. [Google Scholar] [CrossRef]
  33. Cornes, P.; Gascon, P.; Chan, S.; Hameed, K.; Mitchell, C.R.; Field, P.; Latymer, M.; Arantes, L.H., Jr. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Adv. Ther. 2018, 35, 1816–1829. [Google Scholar] [CrossRef] [Green Version]
  34. Grigg, A.; Solal-Celigny, P.; Hoskin, P.; Taylor, K. Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin’s Lymphoma. Leuk. Lymphoma 2003, 44, 1503–1508. [Google Scholar] [CrossRef] [PubMed]
  35. Del Giglio, A.; Eniu, A.; Ganea-Motan, D.; Topuzov, E.; Lubenau, H. XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008, 8, 332. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Engert, A.; Griskevicius, L.; Zyuzgin, Y.; Lubenau, H.; Del Giglio, A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk. Lymphoma 2009, 50, 374–379. [Google Scholar] [CrossRef] [PubMed]
  37. Tamura, K.; Hashimoto, K.; Nishikawa, K. Clinical safety and efficacy of “filgrastim biosimilar 2” in Japanese patients in a post-marketing surveillance study. J. Infect. Chemother. 2018, 24, 363–369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Pinto, L.; Liu, Z.; Doan, Q.; Bernal, M.; Dubois, R.; Lyman, G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: A meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 2007, 23, 2283–2295. [Google Scholar] [CrossRef]
Biology 11 00340 g001 550
Figure 1. Distribution of individual case safety reports having filgrastim and pegfilgrastim as suspect drugs by year (2007–2021).
Figure 1. Distribution of individual case safety reports having filgrastim and pegfilgrastim as suspect drugs by year (2007–2021).
Biology 11 00340 g001
Biology 11 00340 g002 550
Figure 2. Spontaneous reports having the Filgrastim or the Pegfilgrastim as suspect drugs sent through the EudraVigilance database. ICSRs = Individual Case Safety Reports; EEA = European Economic Area; Non-EEA = Non European Economic Area; HCP = Healthcare Professionals; Non-HCP = Non Healthcare Professionals; N.S. = Not specified.
Figure 2. Spontaneous reports having the Filgrastim or the Pegfilgrastim as suspect drugs sent through the EudraVigilance database. ICSRs = Individual Case Safety Reports; EEA = European Economic Area; Non-EEA = Non European Economic Area; HCP = Healthcare Professionals; Non-HCP = Non Healthcare Professionals; N.S. = Not specified.
Biology 11 00340 g002
Biology 11 00340 g003 550
Figure 3. Patient demographic information of adverse events associated with filgrastim.
Figure 3. Patient demographic information of adverse events associated with filgrastim.
Biology 11 00340 g003
Biology 11 00340 g004 550
Figure 4. Distribution of filgrastim- and pegfilgrastim-induced ADRs by outcome.
Figure 4. Distribution of filgrastim- and pegfilgrastim-induced ADRs by outcome.
Biology 11 00340 g004
Table
Table 1. Study of common adverse effects between filgrastim and pegfilgrastim.
Table 1. Study of common adverse effects between filgrastim and pegfilgrastim.
System Organ ClassPT TermFilgrastim ICSRs
(n = 7091)		Pegfilgrastim ICSRs
(n = 10,312)
General disorders and administration site conditions
(n = 6084)		 [n = 2600][n = 3484]
Pyrexia 7.8% (559)6.8% (705)
Drug Ineffectiveness5.7% (407) 5.4% (559)
Death3.4% (244)5.3% (548)
Blood and lymphatic system disorders (n = 4908) [n = 1766][n = 3142]
Neutropenia8.1% (579)10.9% (1129)
Febrile Neutropenia7.4% (526)13.4% (1391)
Thrombocytopenia3.1% (221)1.9% (199)
Musculoskeletal and connective tissue disorders (n = 2662) [n = 1191][n = 1471]
Bone Pain6.6% (473)6.9% (719)
Back Pain4.2% (303)2.3% (240)
Arthralgia3.0% (214)2.5% (267)
Investigations (n = 2740) [n = 1123][n = 1617]
WBC count decreased3.2% (229)3.3% (346)
Platelet count decreased2.1% (155)1.3% (135)
Neutrophil count decreased1.7% (123)2.3% (244)
Table
Table 2. Reporting odds ratio of ICSRs with ADRs belonging to the SOCs “General disorders and administration site conditions”, “Blood and lymphatic system disorders”, “Musculoskeletal and connective tissue disorders” and “Investigations”, for the comparison of filgrastim versus pegfilgrastim.
Table 2. Reporting odds ratio of ICSRs with ADRs belonging to the SOCs “General disorders and administration site conditions”, “Blood and lymphatic system disorders”, “Musculoskeletal and connective tissue disorders” and “Investigations”, for the comparison of filgrastim versus pegfilgrastim.
ICSRsROR (95% CI)p Value
General disorders and administration site conditions1.14 (1.06–1.21)<0.0001
Blood and lymphatic system disorders0.75 (0.70–0.80)<0.0001
Musculoskeletal and connective tissue disorders1.21 (1.18–1.32)<0.0001
Investigations1.01 (0.93–1.10)0.78
Abbreviations: ICSRs = Individual Case Safety Reports; ADRs = adverse drug reactions; SOCs = System Organ Classes; ROR = reporting odds ratio; CI = confidence interval.
Table
Table 3. Reporting odds ratio of ICSRs with ADRs belonging to the top reported ADRs for the comparison of filgrastim versus pegfilgrastim.
Table 3. Reporting odds ratio of ICSRs with ADRs belonging to the top reported ADRs for the comparison of filgrastim versus pegfilgrastim.
ADRsROR (95% CI)p Value
Pyrexia1.16 (1.04–1.30)<0.05
Bone Pain0.95 (0.84–1.07)0.456
Back Pain1.87 (1.57–2.22)<0.0001
Neutropenia0.72 (0.65–0.80)<0.0001
Febrile Neutropenia0.51 (0.46–0.57)<0.0001
Abbreviations: ADRs = adverse drug reactions; ROR = reporting odds ratio; CI = confidence interval.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rastogi, S.; Kalaiselvan, V.; Bin Jardan, Y.A.; Zameer, S.; Sarwat, M. Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database. Biology 2022, 11, 340. https://0-doi-org.brum.beds.ac.uk/10.3390/biology11020340

AMA Style

Rastogi S, Kalaiselvan V, Bin Jardan YA, Zameer S, Sarwat M. Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database. Biology. 2022; 11(2):340. https://0-doi-org.brum.beds.ac.uk/10.3390/biology11020340

Chicago/Turabian Style

Rastogi, Shruti, Vivekanandan Kalaiselvan, Yousef A. Bin Jardan, Saima Zameer, and Maryam Sarwat. 2022. "Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database" Biology 11, no. 2: 340. https://0-doi-org.brum.beds.ac.uk/10.3390/biology11020340

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop